What's New
The information in news releases is current at the time of the release. Note that the information shown here may not be latest information (termination of production or sales, changes to specifications or pricing, organizational or contact address changes, etc.), and may be subject to change without prior notice.
 |
| Changes in Major Shareholder |
| September 9, 2002 |
|
| Toyama Chemical Co., Ltd. (hereinafter referred to as "Toyama") has decided upon allocation of new stock to a third party at the board meeting held on September 9, 2002. Accordingly, the major shareholder in Toyama has been changed as follows: |
|
| 1. | Reason for changes in major shareholders Toyama's allocation of new stock to a third party has been accepted by Taisho Pharmaceutical Co., Ltd. (hereinafter referred to as "Taisho"). |
|||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||
| 2. | Major shareholder | |||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||
| 3. | Number of shares held by Taisho (number of votes) and ratio of shareholding to number of all voting shares | |||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||
| * Number of shares calculated subtracting the number of nonvoting shares from the total number of outstanding shares: 4,079,182 Total number of outstanding shares as of March 31, 2002: 153,766,182 |
||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||
| 4. | Expected date of change: September 26, 2002 | |||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||
| 5. | Perspective after alliance with Taisho Toyama aims to ensure remarkable growth as a research-based company by establishing a strong partnership with Taisho while maximizing investment efficiency in the R&D area through capital alliance with Taisho. |
|||||||||||||||||||||||||||||||||||||||||||||||||